STROKE RISK FACTORS
Atrial fibrillation (AF) is associated with a 5-fold increase in the risk of ischemic stroke.1 Left atrial appendage (LAA) closure reduces the risk of stroke in non-valvular AF patients (NVAF) who are seeking an alternative to oral anticoagulants.2,3
SWITCH TO THE interventional VIEW For more information specific to interventional cardiology regarding LAA Occlusion
2024 EUROPEAN SOCIETY OF CARDIOLOGY (ESC) GUIDELINES FOR THE MANAGEMENT OF ATRIAL FIBRILLATION DEVELOPED IN COLLABORATION WITH THE EUROPEAN ASSOCIATION OF CARDIOTHORACIC SURGERY (EACTS)4-7
|
|
|
|---|---|---|
| IIb | C |
ACCESS TO ALL TREATMENT OPTIONS FOR AF
- Structured support for lifestyle changes
- Anticoagulation
- Rate control
CATHETER AND SURGICAL INTERVENTIONS (ABLATION, LAA OCCLUDER, AF SURGERY, ETC.)
- Antiarrhythmic drugs
- Complex management decisions underpinned by an AF Heart Team
PROFESSOR HANS-CHRISTOPH DIENER
PREVENTION OF STROKE IN PATIENTS WITH AF:
To learn more about the proof of concept studies that led to the current class IIb recommendation for LAAO in the management of AF, please click on the publication link below:
Diener H-C, Landmesser U. Percutaneous left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation.8
TV
TV
Amplatzer™ Amulet™ LAA Occluder
Left Atrial Appendage Occlusion (LAAO)
Anatomical overview of the heart
LAAO Summit - Imaging debate: Mini TEE
LAAO Summit - New data & future trials
LAAO Summit - Debate: Factor XI inhibitors
LAAO Summit - Debate: Factor XI inhibitors
LAAO Summit - Imaging debate: TEE
LAAO Summit - Imaging debate: ICE
LAAO Summit - Pre-procedural imaging
- Amplatzer™ Amulet™ LAA Occluder Instructions for Use.
- Lakkireddy D, Thaler D, Ellis CR, et al. Amplatzer Amulet Left Atrial Appendage Occluder versus Watchman device for stroke prophylaxis (Amulet IDE): A randomized controlled trial. Circulation. 2021; 144(19):1543–1552. doi.org/10.1161/CIRCULATIONAHA.121.057063.
- Suradi HS, Hijazi ZM. Left atrial appendage closure: outcomes and challenges. Neth Heart J. 2017;25(2):143–151. doi.org/10.1007/s12471-016-0929-0.
- Boersma LV, Schmidt B, Betts TR, Sievert H, Tamburino C, Teiger E, et al. Implant success and safety of left atrial appendage closure with the WATCHMAN device: periprocedural outcomes from the EWOLUTION registry. Eur Heart J 2016;37:2465–74. doi.org/10.1093/eurheartj/ehv730
- Reddy VY, Mobius-Winkler S, Miller MA, Neuzil P, Schuler G, Wiebe J, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study with Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol 2013;61:2551–6. doi.org/10.1016/j.jacc.2013.03.035
- Boersma LV, Ince H, Kische S, Pokushalov E, Schmitz T, Schmidt B, et al. Evaluating realworld clinical outcomes in atrial fibrillation patients receiving the WATCHMAN left atrial appendage closure technology: final 2–year outcome data of the EWOLUTION trial focusing on history of stroke and hemorrhage. Circ Arrhythm Electrophysiol 2019;12:e006841. doi.org/10.1161/CIRCEP.118.006841
- Tzikas A, Shakir S, Gafoor S, Omran H, Berti S, Santoro G, et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER cardiac plug. EuroIntervention 2016;11:1170–9. doi.org/10.4244/EIJY15M01_06
- Diener H-C, Landmesser U. Percutaneous left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation. Future Neurol. 2020;15(3).https://doi.org/10.2217/fnl-2020-0001.